BGI•RESEARCH
2.6.2022 10:02:10 CEST | Business Wire | Press release
International scientists led by China’s BGI•Research released the world’s first panoramic spatial atlases of life on May 4, examining the cellular dynamics of organisms at different developmental stages and providing potentially significant new information for disease treatment, development and aging, and an improved understanding of biological evolution.
In a series of studies published in Cell Press journals, members of the Spatio-Temporal Omics Consortium (STOC), an international scientific consortium, used the BGI-developed spatially resolved transcriptomics technology Stereo-seq to produce spatio-temporal cellular maps of mice, Drosophila , zebrafish and the Arabidopsis (thale cress) plant.
The papers demonstrate how Stereo-seq has achieved a major breakthrough in spatial resolution and panoramic field of view, enabling analysis of the distribution and placement of molecules and cells in situ, and over time.
Over 80 scientists from leading universities in 16 countries have so far collaborated as part of STOC focusing on using spatially resolved, cellular resolution omics technologies to map and understand life.
Spatial transcriptomics technology resolves previous issues identifying characteristics of single cells within a biological tissue. It builds on the achievements of single-cell sequencing, elevating it to the next level by enabling scientists to track a cell’s precise location and how it interacts with neighbouring cells.
Scientists used Stereo-seq to examine the early embryonic development of mice, particularly from 9.5 to 16.5 days, during which embryonic development is occurring at a fast rate. Stereo-seq generated the Mouse Organogenesis Spatiotemporal Transcriptomic Atlas (MOSTA), which maps with single-cell resolution and high sensitivity, the kinetics and directionality of transcriptional variation during mouse organogenesis.
“Stereo-seq is a transformational breakthrough in spatial transcriptomics technology and is the most powerful technology in this field of life sciences today,” said Dr. Liu Longqi of BGI•Research, one of the papers’ corresponding authors. “We now have the technology to map a panoramic atlas of every cell in an organism, according to their individual biomolecular profiles, in space and over time.”
“The successful application of our Stereo-seq technology for development has significant implications for the future of genomic research on human diseases,” said co-corresponding author Dr. Xu Xun, director of BGI•Research. “Demonstrating that this technology can pinpoint certain cells that indicate future disease will be critical for diagnostics and therapeutics for a number of conditions.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005196/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenAI and Yubico Partner to Bring Custom Phishing-Resistant YubiKeys to OpenAI Users30.4.2026 19:13:00 CEST | Press release
New strategic, long-term partnership with OpenAI delivers the gold standard of hardware-backed passkeys to the AI ecosystem Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the YubiKey, the gold standard of security keys, today announced an industry-first collaboration with OpenAI, the creator of ChatGPT. Beginning today, people can purchase a new 2-pack set of custom YubiKeys as part of OpenAI’s Advanced Account Security program – enabling them to secure their ChatGPT accounts with security keys, containing the strongest hardware-backed passkeys. Specifically designed for security-conscious users who are at increased risk of targeted digital attacks, the set includes a YubiKey C NFC for tap-to-authenticate on mobile, and a low profile YubiKey C Nano that stays in a port for everyday laptop use – both packed with modern authentication features for the highest level of protection. With OpenAI already using YubiKeys internally to protect
rhode Continues Its Global Retail Expansion Into Sephora Europe30.4.2026 18:00:00 CEST | Press release
This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand rhode, the beauty brand founded by Hailey Rhode Bieber, will be available at Sephora online and in most stores across Europe beginning this September, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion into Sephora Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430569580/en/ rhode continues its global retail expansion into Sephora Europe. rhode’s collection of high-performance, skin-focused products saw strong performance in Sephora U.S. and Canada as the biggest brand launch in the retailer’s history in North America. When launched in November 2025 in the U.K., rhode was also the largest brand launch in Sephora U.K.’s history. “I’m so excited
ABS Acquires RMC Global to Strengthen Cyber, Risk and Resilience Capabilities30.4.2026 17:46:00 CEST | Press release
Acquisition to Deliver Stronger, More Integrated Solutions for Clients ABS, through its affiliate ABSG Consulting Inc. (ABS Consulting), has today announced the acquisition of RMC Global (RMC), a leading provider of industrial cybersecurity, risk management and resiliency solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430164690/en/ (L to R): Vince Kuchar, President, RMC Global, and David Wechsler, President and CEO, ABS Group The acquisition strengthens ABS Consulting’s capabilities and market position, bringing together two organizations with complementary expertise, shared values and a common mission. Combining RMC’s capabilities with ABS Consulting’s scale, technical depth and global resources, unlocks more integrated solutions for clients operating in increasingly complex risk environments. ABS Chairman and CEO John McDonald said: “Clients are facing increasing operational risk, cyber threats, and regulator
Brightfin Unveils AI-Native Platform for IT Financial Management30.4.2026 17:00:00 CEST | Press release
Brightfin clients drive their businesses forward with the first AI Native Cost Optimization Platform Brightfin, the only ITFM and Technology Expense Management solution built natively on ServiceNow, today announced an AI-Native architecture that fundamentally improves how organizations manage IT spend. Rather than bolting AI onto legacy systems, Brightfin has engineered intelligence from the ground up - starting with the data, building contextual awareness on top of it, and delivering AI agents that speak the language of IT finance. Brightfin’s unified budget-to-billing data model creates a stable, governed foundation that connects contracts, invoices, inventory, and budgets into a single source of truth - something no external ITFM tool or native platform module can replicate. This is a structured financial backbone purpose-built for enterprise IT spend, and it’s what makes everything above it possible. A context-aware, AI-Native, intelligence layer understands relationships across th
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 15:22:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom